Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/34687
Title: | Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium | Authors: | VERMEULEN, Helene Coenen, Samuel HENS, Niel BRUYNDONCKX, Robin |
Issue Date: | 2021 | Publisher: | OXFORD UNIV PRESS | Source: | The journal of antimicrobial chemotherapy (Print), 76(10), p. 2725-2732 | Abstract: | Objectives: The criteria for the reimbursement of fluoroquinolones changed in Belgium on 1 May 2018. This study aims to quantify the difference in fluoroquinolone use after this change, and to assess the timing and persistence of this effect, both in terms of total reimbursed fluoroquinolone use and its relative proportion. Methods: Longitudinal reimbursement data on fluoroquinolone use in the Belgian community from January 2017 to November 2018 were analysed to identify a change in reimbursed fluoroquinolone use expressed in DDD per 1000 inhabitants per day (DID), using a set of non-linear mixed models including change-points. In addition , longitudinal data on the relative proportion of prescribed fluoroquinolones from January 2017 to December 2018 were analysed to identify a change in the relative proportion of prescribed fluoroquinolones using generalized estimation equations including change-points. Results: Fluoroquinolone use dropped significantly immediately after the change in reimbursement criteria, from 2.21 DID (95% CI: 2.03-2.38) to 0.52 DID (95% CI: 0.48-0.56) and from 9.14% (95% CI: 8.75%-9.56%) to 6.52% (95% CI: 6.04%-7.04%). The observed decrease in fluoroquinolone use persisted over time. Conclusions: While fluoroquinolone use was still above the target of 5% after the change in reimbursement criteria, its implementation helped to lower fluoroquinolone use in Belgium. | Keywords: | Belgium;Anti-Bacterial Agents;Fluoroquinolones | Document URI: | http://hdl.handle.net/1942/34687 | ISSN: | 0305-7453 | e-ISSN: | 1460-2091 | DOI: | 10.1093/jac/dkab255 | ISI #: | 000701465700033 | Rights: | The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecom mons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
dkab255.pdf | Published version | 653.41 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
5
checked on Oct 14, 2024
Page view(s)
40
checked on Sep 7, 2022
Download(s)
18
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.